 
About the Program
Program Overview
This one-hour Internet symposium will review and discuss the assessment and management of switching antiretroviral classes and agents in virologically suppressed, HIV-positive patients. This symposium will feature an interview of Jose Gatell, MD, PhD one of the leading experts in HIV medicine, by Calvin Cohen, MD, MS, Research Director of CRI New England and Clinical Instructor at Harvard Medical School.
This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.
Back to Top
Target Audience
This activity has been designed to meet the educational needs of physicians involved in the care of patients with HIV infection
Back to Top
Learning Objectives
After completing this activity, participants should be able to:
-
Assess the risks and potential benefits of changing ARV therapy in a patient with an HIV RNA <50 copies/mL;
-
Discuss the differences between various ARV agents and regimens regarding adverse events, including short- and long-term tolerability issues, morphologic and metabolic disturbances, and cardiovascular risk;
-
Describe clinical strategies to minimize ARV risks while maximizing the chance for long-term virologic suppression.
Release Date: December 16, 2010
Expiration Date: December 16, 2011
Estimated time to complete this Web Symposium: 1 Hour
Media: Internet
Back to Top
Course Faculty
Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts
Jose M. Gatell, MD, PhD
Head, Infectious Diseases & AIDS Units, Hospital Clinic
Professor of Medicine, University of Barcelona
Barcelona, Spain
Back to Top
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd, Inc.. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Back to Top
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the bases for content, and appropriateness of patient care recommendations
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|
Calvin Cohen, MD
- Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibtec; ViiV
- Consulting Fees: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec
- Speakers Bureau; Gilead; Bristol-Myers Squibb; Merck & Co.; Tibtec
|
|
Jose Gatell, MD
- Contracted Research: BI; Abbott; BMS; Gilead; Merck & Co.; Pfizer; GSK; ViiV
- Consulting Fees: BI; Abbott; BMS; Gilead; Merck & Co.; Pfizer; GSK; ViiV
|
Disclosure of Unlabeled Use
This educational activity may contain discuion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the period, December 9, 2010 through December 9, 2011 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
You may complete the post-test onlin at: www.cmeuniversity.com
Click on "Find Post-Test/Evaluation by Course" on the navigation menu
Search by project ID: 7541
Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any precedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
Supported by an educational grant from Merck & Co., Inc.
|
